The secretion of insulin is controlled by the rate of glucose metabolism in the pancreatic p cells. As phosphorylation by glucokinase (GLK) appears to be the rate-limiting step for glucose catabolism in p cells, this enzyme may be the glucose sensor. To test this possibility and to resolve the relative roles of liver and fl cell GLK in maintaining glucose levels, we have generated mice completely deficient in GLK and transgenic mice in which GLK is expressed only in p cells. In mice with only one GLK allele, blood glucose levels are elevated and insulin secretion is reduced. GLK-deficient mice die perinatally with severe hyperglycemia. Expression of GLK in p cells in the absence of expression in the liver is sufficient for survival. These mice demonstrate the critical need for p cell GLK in maintaining normal glucose levels and provide a novel model for one form of noninsulin-dependent diabetes.
Introduction
Because both hyper-and hypoglycemia can have significant health consequences, the circulating level of glucose in humans is normally tightly regulated. Insulin, the principal regulator of serum glucose concentrations, is released by the pancreatic p cells in response to an increase in glucose, inhibits glucose production by the liver, and stimulates glucose uptake into muscle and fat. Diabetes mellitus results from either a failure to produce sufficient insulin or an impairment in the response to insulin.
Understanding how the 0 cells sense an alteration in glucose levels is critical to understanding how glucose homeostasis is maintained. Glucose sensing is mediated through an increase in the rate of intracellular catabolism of glucose rather than a ligand-receptor interaction (Grodsky et al., 1963; Coore and Randle, 1964 ; reviewed by Cook and Taborsky, 1990) . However, it is likely that there is still a need for a rate-limiting step in glucose catabolism to serve the role of glucose sensor. A compelling case has been made for glucokinase (GLK) fulfilling this role (reviewed by Matschinsky et al., 1993) .
GLK is one member of the hexokinase family (reviewed by Cornish-Bowden and Cardenas, 1991) . It has a high substrate specificity for glucose and has a relatively high K, of about 10 mM (versus 0.1-0.001 mM for the other hexokinases). The enzyme has a sigmoidal glucose dependency with an inflection point around the physiological glucose concentration (5 mM glucose). Furthermore, the rate of glucose phosphorylation appears to be significantly less than the rate of glucose entry into the p cells via GLUT2, the b cell-liver glucose transporter Liang et al., 1994) . These characteristics are consistent with the possibility that GLK is the main glucose sensor in the p cell (reviewed by Mueckler, 1993; Matschinsky et al., 1993) .
The genetic analysis of a relatively mild form of noninsulin-dependent diabetes mellitus (NIDDM) known as maturity onset diabetes of the young (MODY) also suggests that GLK is the primary glucose sensor in the p cells. MODY is inherited as a single dominant mutation. In about 50% of patients, MODY is associated with mutations in the gene encoding GLK (Hattersleyet al., 1992; Froguel et al., 1993; Vionnet et al., 1992; Katagiri et al., 1992; Sun et al., 1993; Velho et al., 1992) . These mutations result in altered GLK activity when the appropriate Escherichia coli derived forms are analyzed GidhJain et al., 1993) . GLK mutations have also been reported in a subset of patients with gestational diabetes and in a small number of Japanese NIDDM patients (Katagiri et al., 1992) . There are no reports of individuals who completely lack GLK.
Functional GLK protein appears to be made mainly in the pancreatic p cells and in liver. A GLK-like protein may also be produced in jejunal enterocytes, the pituitary, and the medial hypothalamus . In the liver, GLK may participate in the regulation of glucose uptake or output by maintaining a concentration gradient for glucose. The role of GLK in the other tissues is unclear. Both the rat (Magnuson and Shelton, 1989) and the human (Koranyi et al., 1992) GLK genes are transcribed using two different promoters. The resulting transcripts differ only in their S/ends, leading to two proteins with different N-termini. The liver-specific promoter is induced by insulin . The other promoter is used in fi cells (and possibly other tissues). Transcription in p cells does not appearto be regulated by insulin; instead, GLK activity seems to be controlled on a translational or posttranslational basis according to glucose levels (Bedoya et al., 1986; Liang et al., 1992 ; reviewed by Magnuson, 1992) .
Some aspects of the role of GLK in glucose homeostasis have been addressed by performing whole-body analysis on patients with MODY. However, there are several significant questions that would be difficult to address in human patients but could be approached by a combination of gene knockouts and transgenes in mouse models. First, what are the consequences of a complete lack of GLK? It is possible that alternate enzymes (the hexokinases) can be up-regulated and compensate for the absence of GLK. Second, how much of the hyperglycemia in MODY patients is caused by a reduction in liver as compared with fi cell GLK activity? Third, as glucose stimulates transcription of the insulin gene and translation of the insulin mRNA, does the level of GLK affect these activities? Fourth, what effect would an absence of GLK have on the other tissues (enterocytes, brain, and pituitary) that are known to be glucose responsive?
We have used a combination of gene inactivation and transgenic strategies to produce mice that have either one normal and one inactive GLK allele, two inactive GLK alleles, or expression of a 8 cell-specific GLK transgene but no functional GLK in any of the other tissues. Mice with one functional GLK allele develop a mild diabetes, comparable to that seen in the MODY patients, and mice completely deficient in GLK are extremely diabetic and die approximately 5 days after birth (P5). Expression of GLK in 6 cells in the absence of GLK in the liver is sufficient for survival and, at least in some mice, to maintain near normal glucose levels. Figure 1 , and details of the construction are given in Experimental Procedures. Two independent embryonic stem (ES) cell lines transmitted the mutation and gave rise to two GLKdeficient mouse lines (GLKa and GLKb). The founder mice were bred to either C57BL16J or DBA12J mice to generate mice that are heterozygous for the mutation, hereafter referred to as GLK (+I-) mice. Intercrosses between GLK (+I-) mice yielded GLK (-I-) mutants. The wild type, heterozygotes, and the homozygotes were born with the expected 1:2:1 ratio, but GLK (-I-) mice died at postnatal days 3-5 (P3-P5). These mice are markedly diabetic (see below), which could account for the mortality. Alternatively, as these mice appear to stop feeding at around P3, they could be dying from starvation. The principal sites of expression of GLK are the 6 cells and the liver. Both organs are critically involved in glucose homeostasis.
Thus, we anticipated that interpretation of the GLK deletion results would be aided by having mice that expressed GLK in the 6 cells but were GLK deficient in all of the other tissues. To accomplish this, we generated transgenic mice carrying the 8 cell GLK cDNA isoform under the control of the human insulin promoter plNS.GLK.HBS (see Experimental Procedures). Three lines of transgenic mice were selected for two generations of intercrossing with the nontransgenic GLK (+I-) mice to obtain all six possible combinations of transgene and knockout mutations. For the transgenic line, described in Table 3 , all six combinations were born at close to the expected frequency.
With the exception of the nontransgenic GLK (-I-) mice, there appears to be no increase in perinatal mortality. The genotype of the relevant mice (the status of the endogenous GLK locus and transgene presenceversus no transgene) was determined (A) The exonlintron structure of the mouse GLK is drawn using the known structure of the rat and human genes as guides. Not all mouse introns have been sequenced Magnuson and Shelton, 1989) . (B) Targeting construct consisting of Ex2-Ex3 and fx56-Ex70r PCR fragments, separated by the neo resistance gene. (C) GLK 8 cell transgene vector, constructed from human insulin promoter with the noncoding insulin exons 1 and 2(stippled boxes; Sarvetnik et al., 1988 ) mouse 8 cell GLK cDNA (exons 18-10; boxes with vertical lines), and HBS terminator (hatched box; Sarvetnik et al., 1988) . (D and E) Mouse tail DNA PCR to confirm the presence of the GLK mutant allele by using primers 528-Neo7 (an expected size of 0.8 kb) (D) and using primers Ex5-ExlOi (an expected size of 5 kb) (E). Note that primer 528 (D) and primer ExlOi (E) are outside the targeting construct and that the sequence for primer Ex5 (see [A] ) is deleted in the targeting construct.
by polymerase chain reaction (PCR) analysis of genomic DNA taken from a tail biopsy using appropriate primers.
GLK Activity in Liver and Islets of GLK Mutants Expression of the endogenous and transgenic GLK alleles in the liver and islets was determined by enzymatic and Northern blot hybridization analysis. GLK activity was reduced in mice with only one functional allele, GLK (+I-) (Table 1 ). In the liver of GLK (+/-) mice, V,,, was reduced to 234 f 37 nmollmg protein per hour compared with 418 + 42 nmollmg protein per hour in GLK (+/+) mice. In islets from GLK (+I-), V,,, is reduced by the same percentage as in the liver (3.0 mollkg DNA per hour versus 5.2 mall kg DNA per hour). Hexokinase activity was not obviously altered in either the liver or islets (data not shown). An mRNA species of approximately 2.4 kb was detected in the RNA from livers of wild-type animals and, at reduced intensity, in the heterozygotes.
This mRNA was not detectable in the transgenic homozygous mice (Figure 2A) , and there was no detectable GLK activity in the livers of these mice (data not shown). A 4 kb mRNA, probably derived from the mutated allele, was detected in mice with at least one mutant GLK allele. This mRNA hybridized with both theGLKcDNAandwithaneoprobe(Figure2B).Additional smaller bands hybridizing to the neo probe were also detected (data not shown). These may have been derived by alternate splicing or termination of the transcript from the GLK mutant allele.
That the transgene is expressed in the islets of the transgenic mice was demonstrated by reverse transcription PCR (RT-PCR). A fragment of the appropriate size (0.8 kb) was detected after analysis of the RNA from transgenic islets but not from nontransgenic islets ( Figure  2D ). An additional product, which is detected in some transgenic islets, appears to be due to nonspecific hybridization of the transgene-specific primer HBSr (see Figure  1D ) during PCR. Figure 1C ). The blot was probed with an oligo that is internal to the PCR fragment. (E) Aliquots of the islet cDNA used in (D) were used in a PCR with GAPDH primers to demonstrate that approximately equivalent amounts of RNA were used in (D) and to confirm the successful generation of first-strand cDNA.
A detailed analysis of the enzymatic activity provided by the different transgenes and the effects on glucose homeostasis is in progress. Preliminary analysis indicates that the level of GLK activity in the islets of the transgenic knockout mice described in this section is greater than that seen in the heterozygotes but less than the wild-type mice (data not shown). This transgenic line, in which the transgene is expressed in the islets but not in the liver, forms the basis for the results described below.
Phenotypic Consequences of the GLK Mutation
We investigated the effect of reduced GLK activity on blood glucose levels and whether this is modified by sex, age, mouse strain, or diet. Results are presented from the analysis of the GLKb line if not otherwise noted. The data obtained from mice in the GLKa line are not distinguishable from the results obtained from the GLKb mice.
At Pl , mice homozygous for the GLK mutation, GLK(-/-), have dramatically increased glucose values, 24.0 f 4.0 mM compared with 2.9 + 0.3 mM in GLK (+I-) and 3.4 f 0.2 mM in GLK (+I+) mice (Table 2 ). These mice are slightly smaller from the day of birth (data not shown) and die by P3-P5. The heterozygotes also develop higher glucose levels from birth, although well below those seen in the GLK-deficient mice. The weight of the heterozygotes is not obviously different from the controls, and these mice develop normally and are fertile.
Histological analysis revealed differences only in the livers of perinatal (P2 and older) GLK (-I-) mice ( Figure 3 ). All other organs examined (brain, heart, intestine, kidney, lung, pancreas, skeletal muscle, spleen, stomach, and thymus) appeared to be normal, and by immunocytochemistry there was no detectable difference in pancreatic insulin levels in neonatal GLK (+/+) and GLK (-I-) mice (data not shown). In the livers of perinatal GLK (-I-) mice, there is a significant reduction in liver glycogen stores (compare Figure 38 with Figure 3E ), and an increase in vacuolization and lipid accumulation was observed as microvesicular steatosis (compare Figure 3C with Figure 3F ). The heterozygotes appeared normal. That there are abnormalities in lipid metabolism is further indicated by an analysis of serum cholesterol and triglyceride levels (Tables 2 and 3 ). Both total cholesterol and triglycerides were elevated in the P3 GLK (-I-) mice, whereas only the triglycerides were significantly higher in the Pl GLK (-I-) mice.
In adult GLK (+I-) mice (males and females), random (nonfasted) glucose values are significantly higher than those in GLK (+/+) mice (Table 3 ; p < 0.001). This increase in blood glucose values was observed from birth (see Table 2 ) through the test period of 8 months (Table 3 ; data not (+I+) Comparisons are not made among different ages; n = 6. Data were analyzed by two-way ANOVA. Group differences were evaluated with Fishers PLSD test. a p value is significantly different from that of (-I-) genotype. b p value is significantly different from that of (+/-) genotype. ' p value is significantly different from that of (+/+) genotype.
shown). The diminished GLK activity in the heterozygotes also caused a comparable increase in the glucose levels (170% of wild type) in fasted mice (data not shown).
As glucose levels in MODY patients appear to be sensitive to body mass index (Katagiri et al., 1992) we put a cohort of GLK (+I-) mice on a high fat diet at 4 weeks. The high fat diet caused a small increase in the weights of the mice (5.2 g in males and 2.1 g in females at 22 weeks of age). While there was an effect of diet on the random glucose levels at 7 weeks of age, there was no obvious effect at 22 weeks, and there was no apparent effect on fasting glucose levels (data not shown). Both the C57BL16J and DBA/2J GLK (+I-) mice have comparable hyperglycemia in comparison with wild-type littermate controls (data not shown). Strain-dependent effects may become detectable with further backcrosses.
The effect of the expression of the 6 cell-specific transgene on the glucose level depends on the status of the endogenous GLK genes. In wild-type mice, the transgene appears to lower the glucose levels slightly, but this effect was not statistically significant (Table 3 ). The transgenie heterozygotes have glucose levels that are not significantly different from nontransgenic wild-type mice but that are significantly less than those measured in the nontransgenic heterozygotes. In the homozygous knockout mice, the transgene provided the difference between survival and perinatal death. These transgenic homozygous mice had glucose levels that were 12.9 f 1.5 mM as compared with 6.3 f 0.5 mM in the transgenic heterozygotes and 10.4 f 0.4 mM in heterozygous mice. Although the mean glucose levels in the transgenic homozygous mice are clearly higher than those measured in the wildtype mice, approximately 50% of these mice have random glucose levels that are consistently within the normal range.
The transgenic knockout mice have moderately elevated glucose levels but are otherwise healthy and are fertile. The histologically obvious pathology that appears in the P3 knockout mice is also to a large extent reversed (data not shown). More detailed analysis may reveal more subtle structural or metabolic differences.
To define further the impact of altered GLK expression on glucose homeostasis, we performed glucose challenge studies. In comparison with wild-type mice, the heterozy- gotes have an impaired ability to dispose of injected glucose, whereas in the transgenic heterozygotes, the mean glucose levels were not distinguishable from the wild-type mice ( Figure 4A ). In the transgenic knockout mice, the mean glucose levels were significantly higher than in any of the other groups ( Figure 4A ). There is more variation in the glucose values obtained with the transgenic knockouts thaninanyothergroupsandslightlymorein thetransgenic heterozygotes than in the nontransgenic heterozygotes. This variation becomes more obvious when the curves for the individual mice are plotted (Figure 48 ). These individual curves reveal responses that range from diabetic (a 1 hr value of greater than 11 mM) to several mice that returned to the initial values considerably faster than normal. Comparable curves are given in Figure 4C for the transgenic knockouts. Within this group there also appear to be several discrete phenotypes.
From both an analysis of the numbers of transgenic animals born and gene structure analysis, there is no evidence to support the possibility that this variability derives from there being independently segregating transgenes with different levels of expression (data not shown). Furthermore, for individual mice, the glucose disposal curves were not significantly different when retested 2 months later.
Impact of the GLK Mutation on Insulin Levels and insulin Secretion
Although the GLK (+/-) mice have higher glucose levels than the wild-type mice, the nonfasting insulin levels were not significantly different (data not shown). The difficulty in interpreting insulin levels in mice with different glucose values was overcome by using an organ perfusion approach ( Figure 5 ). Pancreata from GLK (+/-) mice have no recognizable first-phase response while perfused with 5 mM glucose. Increasing glucose to 11 mM resulted in a low first-phase response (1.5 nglml versus 7 nglml in wild type). The second-phase response was marginally above the 0 mM baseline. Stimulation with 22 mM glucose doubled the first-phase response compared with the 11 mM stimulation (3 rig/ml versus 10 nglml for wild type), while the second-phase remained low (2 rig/ml versus 8 nglml in wild type). A detailed analysis of insulin secretion in comparison with the level of GLK expression in mice with the other combinations of GLK alleles (transgenic versus nontransgenic and heterozygotes versus knockouts) is in progress and will be published elsewhere. 
Discussion

GLK (+I-) Mice Are Hyperglycemic
Mice that have only one normal GLK allele express lower levels of functional GLK protein, have an impaired f3 cell response to glucose, and are hyperglycemic.
Two lines of GLK-deficient mice generated from independent clones of targeted ES cells have comparable hyperglycemia, supporting the conclusion that the phenotypic changes are due to the mutation in the GLK gene rather than to a separate but tightly linked mutation that arose in the ES cells. The insulin levels in these hyperglycemic GLK-deficient mice are not significantly different from their normoglycemic littermates.
This decreased insulin/glucose ratio suggests an increase in insulin sensitivity. The insulin levels in hyperglycemic MODY patients are also not significantly different from the controls (Katagiri et al., 1992; Byrne et al., 1994) .
GLK Compensation
The reduction in the level of GLK activity in those mice with only one functional allele implies an inadequate regulation of GLK expression to compensate for the loss of one allele. Regulation of GLK expression is complex (reviewed by Magnuson, 1992) . There are two independent tissue-specific promoters and first exons. The 5'promoter and first exon are used in f3 cells, and the more 3'promoter and first and second exons are used in the liver. GLK activity in the liver appears to be primarily controlled by insulin-mediated regulation of transcription , whereas in p cells, GLK activity may be controlled by glucose through increased translation or reduced degradation of the enzyme (lynedjian et al., 1989; Liang et al., 1992) or directly on GLK activity (Chen et al., 1994) . If insulin is the primary mediator of GLK levels in the liver, then the lack of compensation in this organ could be explained by the observation that heterozygous mice have insulin levels comparable to the wild-type mice. In b cells, GLK activity appears to be positively regulated by glucose, and the metabolism of glucose is positively regulated by the level of GLK activity. This suggests the presence of a self-reinforcing feedback loop inside the p cell counterbalanced by a negative feedback loop acting through glucose-stimulated insulin secretion. Thus, it is possible that a reduction in GLK activity (by, for example, the loss of one allele) would also reduce the ability of the f3 cell to recognize the decrease. Although there seems to be little compensation in these mice for the loss of one GLK allele, in at least some patients with MODY, there does appear to be a mechanism that partially compensates .
Insulin Secretion
Heterozygotes with their GLK activity reduced (57%) have an impaired ability to secrete insulin in response to an increase in glucose. In spite of this impairment, these heterozygotes have circulating insulin levels comparable to the wild-type mice. This result is expected from the combination of the decreased sensitivity of the pancreata to glucose and the increase in circulating glucose. At 11 mM glucose, the heterozygous pancreas will release approximately the same amount of insulin as is released by the wild-type pancreas stimulated by the physiological concentration of 5 mM ( Figure 5 ). These glucose concentrations (5 mM in the wild-type mice and 11 mM in the heterozygotes) are close to those present in the circulation of these animals (Table 3) . Comparable considerations can be made with respect to the glucose concentration required in the heterozygotes to match the GLK velocity in the wild-type mice at 5 mM glucose (see Table 1 ). These results are consistent with the possibility that the level of GLK activity is responsible for the glucose setpoint as well as acting as the glucose sensor. When the starting glucose concentrations are normalized, insulin secretion rates in MODY patients are also significantly less than in controls .
A reduction in (j cell GLK has been obtained using an antisense transgene approach (Efrat et al., 1994) . This led to a reduced sensitivity of the p cells to glucose, but there was no alteration in circulating glucose levels. An increase in f3 cell hexokinase levels has been achieved in both isolated islets and in transgenic mice (Becker et al., 1994; Voss-McGowan et al., 1994) . Although a significant increase in the level of hexokinase expression (5 to 8-fold) was obtained, the subsequent increase in glucose utilization and insulin secretory response to glucose was less (8fold). It was suggested that this may have been a consequence of other components of the 0 cell response becoming rate limiting at the high hexokinase levels that were obtained.
Although not directly determined through pancreas perfusion, the marked hyperglycemia in the GLK (-/-) mice suggests that insulin secretion is even more impaired in these mice. Insulin release in these mice may be induced by glucose metabolism through hexokinase in combination with stimuli from amino acids, fatty acids, glucagon, and other compounds.
Consequences of Complete GLK Deficiency
Mice that are completely deficient in GLK are born at the expected frequency with no obvious pathological lesions in the major organs. They are, however, markedly hyperglycemic, and there are histological changes in the liver that become apparent by P2. These liver changes include microvesicular steatosis and a depletion of glycogen. In addition, there is an increase in circulating triglycerides. An increase in liver uptake of lipids subsequent to this hypertriglyceridemia may be responsible for the hepatic steatosis. The alternative of an increase in hepatic lipid synthesis is less likely given the relative decrease in insulin secretion in these mice. Liver glycogen is decreased in the homozygotes.
Glycogen is derived from circulating glucose (after phosphorylation by GLK) or from gluconeogenesis. As glycogen synthesis is stimulated and glycogenolysis is inhibited by insulin, the relative reduction in insulin that occurs in the GLK-deficient mice should lead directly to a loss of liver glycogen. The marked imbalance between glucose-6-phosphatase and GLK that is present in the livers of these mice may mean that an additional control point, the direct inhibitory effect of glucose on glycogenolysis, may be missing (Rossetti et al., 1993) .
The complete loss of GLK is fatal, usually by P5. As the mice are markedly hyperglycemic from birth (22-33 mM), it is possible that they die from coma caused by hyperosmolality.
Transgenic Rescue of GLK-Deficient Mice
It is not known whether the diabetes in patients with MODY is caused by a deficiency in f3 cell GLK or hepatic GLK (or both). To separate out the effects of 6 cell versus liver GLK deficiency, we have generated transgenic mice in which a mouse 6 cell GLK cDNA is expressed from the human insulin promoter.
The 6 cell GLK transgene has a marked effect on GLK (-I-) mice: the transgenic mice survive, whereas the nontransgenic GLK (-I-) mice die perinatally with extreme hyperglycemia.
The presence of p cell GLK in the complete absence of liver GLK is sufficient to completely normalize some (cholesterol and triglycerides  [Tables 2 and 31 , as well as blood urea nitrogen, albumin, and total protein [data not shown]), but not all (fasting and fed glucose; Tables 2 and 3; Figure 4C ) abnormalities that were detected in the P3 GLK-deficient mice. Although the mean glucose levels (random and following an intraperitoneal glucose tolerance test) are higher in the transgenic homozygous mice than in the wild-type mice, approximately 50% of these transgenic homozygous mice have glucose levels that are indistinguishable from wild-type mice. The glucose control in the heterozygous mice is clearly abnormal, whereas the transgenic heterozygotes have mean fed and fasting glucose levels that are not distinguishable from wild-type mice, and the mean glucose profiles following an injection of glucose also appear normal.
Thus, provided that 6 cell GLK levels are sufficient, it is possible to maintain normoglycemia in the presence of only one functional GLK allele in the liver. Even in the complete absence of liver GLK, it is possible to maintain glucose levels that are near normal or, in some cases, indistinguishable from normal.
Heterogeneity between Individual Mice
Mice with the same genotype with respect to either the endogenous GLK gene or the GLK transgene can have markedly different fed and fasted glucose levels and responses to injected glucose. This increased variability is obvious in both the variability in the mean glucose levels (Table 3 ) and in the glucose challenge studies ( Figure 4A ). The increased variation that is apparent in comparisons between wild-type and heterozygous mice is also seen in comparisons between the transgenic and the nontransgenie mice.
Following the cross that generated the transgenic knockout mice, there are segregating alleles derived from the 129/Sv, C57BL/6J, and SJUJ mouse strains. It may be that the phenotypic heterogeneity is derived from this genetic heterogeneity.
This genetic heterogeneity appears to have an effect in those mice with decreased expression or an altered pattern of expression of GLK but little impact in the context of normal GLK expression. Intercrossing of mice with selected glucose-related phenotypes is in progress to examine this. It has been noted that within MODY families with the same GLK mutation, some family members will be diabetic whereas others will be more modestly affected with either glucose intolerance or mild fasting hyperglycemia (Hattersleyet al., 1992; Froguel et al., 1993 ) and these differences may be exaggerated by changes in the body mass index (Katagiri et al., 1992) .
Hepatic Glucose Output
In individuals with diabetes, an increase in gluconeogenesis and hepatic glucose output (HGO) is primarily responsible for the fasting hyperglycemia.
The level of HGO appears to be primarily controlled by the relative rates of glucose phosphorylation by GLK and dephosphorylation by glucose-6-phosphatase (reviewed by Davis and Pagliassotti, 1994) . Theobservation that the heterozygous mice have diminished liver GLK activity and have an increase in fasting glucose is consistent with there being an increase in HGO in these mice. The availability of mice that have reduced hepatic GLK in the presence of near-normal levels of glucose, insulin, and 6 cell GLK will provide an opportunity to evaluate directly the role of hepatic glucose phosphorylation in the regulation of HGO.
GLK in NIDDM
The possibility that alterations in GLK expression are involved in the more common forms of NIDDM has been investigated. Although there have been reports of positive genetic associations in selected racial groups (Chiu et al., 1992a (Chiu et al., , 1992b Elbein et al., 1993; Noda et al., 1993; McCarthy et al., 1993) , in others there has been no association . Furthermore, family studies have in general failed to demonstrate linkage or GLK mutations even in those situations in which there was association (McCarthy et al., 1993; Elbein et al., 1993; . In a separate report, two individuals (of 40 screened), with both gestational diabetes and a relative with NIDDM, had mutations in one of their GLK alleles and in one group of obese NIDDM patients, there was a significant decrease (50%) in hepatic GLK activity in comparison with either lean or obese nondiabetic individuals (Caro et al., 1995) . Although it appears that mutations in the GLK gene are relatively rare in the more common forms of NIDDM, it is possible that genetically determined alterations in other proteins (for example, the GLK regulatory protein or transcription factors) could indirectly couple GLK to the development of NIDDM.
Conclusion
Mice that have one functional GLK allele have a diminished b cell response to glucose and are hyperglycemic, whereas mice that completely lack GLK are markedly diabetic at birth and die, usually by P5. Mice that express GLK exclusively in the f3 cells survive and have glucose levels that range from normal to moderately diabetic. These transgenic knockout mice point to b ceil GLK having a greater impact on glucose homeostasis than liver GLK and provide strong support for the concept that GLK is the primary b cell glucose sensor.
Experimental Procedures
Construction of Replacement and Transgene Vectors The GLK replacement vector (pRKTK.GLK) was generated in several steps. A 0.6 kb 5' genomic and a 4.5 kb more 3' genomic GLK DNA fragment was isolated from purified mouse ABl ES cell DNA by PCR. The primers used for these PCRs were located in exon 2 (fx2) and exon 3 (Ex3) and in exon 5 (fx5b) and exon 10 (ExlOr), respectively. The sequences of these and all other oligonucleotides are available on request. The two PCR products were subcloned such that the fx2-Ex3 fragment is flanked on the 5' side by the herpes simplex virus thymidine kinase gene under the control of the CMV promoter, and the two genomic fragments are separated by the neo resistance gene under the control of the PGK promoter. The PGK-neo gene is in the same transcriptional orientation as the GLK gene.
To construct the transgene, we amplified the GLK cDNA by RT-PCR from C57BU6J islet RNA with the E76-2 and the ExlOioligonucleotides as PCR primers. The PCR fragment was subcloned, completely sequenced in both directions, and inserted into plnspro (Sarvetnik et al., 1968) to generate plNS.GLK.HBS.
Generation of Knockout Mice ABI ES cells (passages 1 l-1 3) were grown on mitomycin C-treated G418-resistant ST0 cell feeder layers (Robertson, 1987) in DMEM containing 10% fetal bovine serum and 0.1 mM 6-mercaptoethanol at 37% and 5% CO*. The ES cells were electroporated (4 x lo5 cells in 0.4 ml of PBS and 16 ug of Notl-linearized pRKTK.GLK DNA) in a 0.4 cm cuvette of a Bio-Rad Genepulser set at 230 V, 500 uF, and 600 ohms. Electroporated cells were plated, and G418 (ZOO uglml effective concentration; Sigma) and gancyclovir (2 PM) were added 48 hr later. Surviving clones were picked into 96-well plates coated with feeder ST0 fibroblasts and expanded for DNA isolation. DNA from the cells was analyzed for homologous recombination by PCR with a GLK forward primer that was outside the targeting vector (primer 528) located in Ex2 of the GLK gene and with a reverse primer, Neal, located in the neo resistance gene. Cells that had undergone homologous recombination gave a diagnostic 0.8 kb PCR fragment. Positive results were confirmed by Southern blot analysis.
We used three cell clones that were positive for homologous recombination for microinjections into the blastocoel cavity of P3.5 C57BU 6J blastocysts (Hogan et al., 1986) . Agouti-colored male mice derived from these injected blastocysts were test bred with C57BU6 females and their agouti offspring screened for germline transmission by tail DNA PCR with primers 528 and Neal. All subsequent offspring were analyzed by tail DNA PCR.
Generation of Transgenic
Mice A 4.6 kb Asel restriction fragment was isolated from plNS.GLK.HBS and used for injection into i-cell stage (SJL x C57BU6J) x (SJL x C57BU6J) embryos (Sarvetnick et al., 1988) . Transgenic mice were identified by Southern blot analyses of DNA extracted from the tails. Subsequently transgenic mice were identified by PCR from tail DNA with Ex5 and Ex6r PCR primers, yielding a 0.18 kb band for the transgene and a 0.3 kb band for the wild-type allele.
To generate transgenic knockout mice, GLK (+I-) mice were bred to transgenic GLK mice. Resulting transgenic GLK (+I-) mice were intercrossed to GLK (+/-) mice to generate transgenic GLK (+I+) mice. Genotyping was performed by tail DNA PCR with primer sets 528-Neal (mutant allele) and Ex5-Ex6r (wild-type allele and transgene, respectively; note that the sequence for Ex.5 is deleted in the mutant allele).
Northern Blots Total RNA was isolated from islets or liver with RNA STAT-60 (TEL-TEST 6, Incorporated). To purify poly (A)+ RNA, we used the polyATract mRNA isolation system (Promega). Poly(A)'(2 ug) mRNA or total RNA (20 ug) was loaded on a 0.9% agarose, 6% formaldehyde gel, electrophoresed, transferred to a nitrocellulose membrane, and hybridized to the GLK cDNA fragment.
Analytical Procedures
Blood glucose values were determined from whole venous blood by using an automatic glucose monitor (One Touch II, Lifescan). Insulin levels were measured by RIA (rat insulin RIA kit, Linco) from portal vein blood. Cholesterol and triglyceride analyses were performed from serum samples on a Hitachi analyzer.
Glucose Challenge Overnight fasted mice were injected intraperitoneal with 1 g of glucose per kilogram of body weight. Blood glucose values were measured immediately before and 10, 20, 30, 60, 120, and 180 min after the injection.
Hexokinase and GLK Assays Glucose phosphorylating activity was analyzed either from freshly prepared mouse islets (>400) or liver by a fluorometric assay measuring NADH formation. The methods are described by Trus et al. (1981) and Liang et al. (1991) . In brief, islets were washed free of glucose and homogenized (20 mM &HP04, 5 mM DTT, 1 mM EDTA, 110 mM KCI) on ice. An aliquot was taken to determine DNA content (Labarca and Paigen, 1980) . Homogenized islets were centrifuged for 10 min at 12,000 x g to remove mitochondrial bound hexokinases. We added 5 ul of supernatant to 100 ul of reaction buffer (50 mM HEPES [pH 7.61, 100 mM KCI, 15 mM 6-mercaptoethanol, 7.4 mM MgC&, 0.5 mM NAD', 5 mM ATP, 0.05% BSA, 0.7 U/ml glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides) and incubated the mixture with varying glucose concentrations (0, 0.03, 0.06, 0.125, 0.25, 0.5, 6, 12, 24, 60 , and 100 mM) for 90 min at 30%. The reaction was stopped by addition of 2 ml of 0.5 M NaHC03 (pH 9.4). Glucose-Bphosphate standardsand reagent blanks wereincluded. Each reaction was performed in triplicate. NADH formation was measured fluorometrically (350 or 460 nm). K, and V,,, values were calculated from EadieScatchard plots including an additional correction method according to Spears et al. (1971) with 10 correction cycles. Liver hexokinase and GLK were assayed in the same way with the exception that homogenized liver extracts were centrifuged at 100,000 x g at 4'C for 70 min. Of the supernatant (about 5 mg of wet liver weight per milliliter of supernatant), 5 pl was used for the above assay. Kinetic data for liver samples were calculated according to total protein amount (Bio-Rad).
In Vitro Pancreas Perfusion The pancreata with adjacent duodenum were surgically removed from pentobarbital-anesthetized fed mice (100 mg/kg body weight) and perfused as previously described (Ma et al., 1994) . In brief, perfusate consisting of bicarbonate-phosphate-calcium buffer with 0.2% purified stabilized BSA and 3% Dextran T-40 was introduced into the celiac artery at 0.9 ml/min. Effluent was collected at 1 min intervals from the portal vein after single passage through the tissue, and the insulin secreted was assayed. At the end of each experiment, pancreatic insulin content was determined by extracting insulin from homogenized pancreata in acid-alcohol (alcohol:H20:concentrated HCI at a ratio of 750:235:12).
Histological
Analyses A portion of removed organs was fixed in neutral buffered formalin, embedded in paraffin, then sectioned, and stained with hematoxylin and eosin. Sections of liver were stained by periodic acid-Schiff reagent (PAS) with and without diastase digestion to demonstrate glycogen. Pancreas was stained for insulin by immunoperoxidase. Liver cryosections were stained for lipid by oil red 0.
Statistical Analyses Each variable was analyzed by a two-way analysis of variance (ANOVA). We used Fisher's protected least significant difference (PLSD) test (p < 0.05) to evaluate group differences. For all analyses, a p value of less than 0.05 was considered significant. Results are given as means r 1 SEM.
